BEAT Rules Could Kill Clinical Trials, Industry Claims
U.S. Treasury rules administering the 2017 tax law's base erosion and anti-abuse tax represent an "existential" threat to the business model of companies that administer clinical trials for pharmaceutical firms, two...To view the full article, register now.
Already a subscriber? Click here to view full article